While immune checkpoint blockade has shown encouraging effects in subtypes of NSCLC patients, relatively poor response in EGFR mutant NSCLC patients means that those patients who develop resistance to EGFR inhibitors have no effective treatment options. This evidence concerns the gene EGFR and non-small cell lung carcinoma.